

Influenza Vaccine Product List and Age Groups --- United States, 2016-2017 Season¹ (updated 29 Nov 16)
(DOD contracted vaccines are highlighted)

Manufacturer	Trade Name	Presentation	Mercury (thimerosal) µg/0.5 mL	Ovalbumin µg/0.5 mL	Age Group	CVX	CPT
Seqirus, Inc. (formerly bioCSL and Novartis)	Afluria ¹ (IIV3)	0.5 mL single-dose prefilled syringe	0.0	< 1	≥ 9 yrs ²	140	90656
		5 mL multi-dose vial ^{3,4}	24.5	< 1		141	90658
	Afluria ¹ (IIV4)	0.5 mL single-dose prefilled syringe	0.0	< 1	≥ 18 yrs	150	90686
		5.0 mL multi-dose vial ^{3,4}	24.5	< 1		158	90688
	Fluvirin ¹ (IIV3)	0.5 mL single-dose prefilled syringe (latex in tip caps)	≤ 1	≤ 1	≥ 4 yrs	140	90656
		5 mL multi-dose vial	25.0	≤ 1		141	90658
	Flucelvax ¹ (cIIV4)	0.5 mL single-dose prefilled syringe	0.0	††		171	90674
	Fluad ^{1,5} (IIV3)	0.5 mL single-dose prefilled syringe (latex in tip caps)	0.0	< 0.4	≥ 65 yrs	168	90653
GlaxoSmithKline	Fluarix ¹ (IIV4)	0.5 mL single-dose prefilled syringe	0.0	≤ 0.05	≥ 3 yrs	150	90686
ID Biomedical Corp of Quebec (subsidiary of GSK)	FluLaval ¹ (IIV4)	0.5 mL single-dose prefilled syringe ¹⁰	0.0	≤ 0.3	≥ 6 mos	150	90686
		5 mL multi-dose vial ^{4,10}	< 25.0	≤ 0.3		158	90688
Sanofi Pasteur	Fluzone ¹ (IIV4)	0.25 mL single-dose prefilled syringe	0.0	§§	6-35 mos	161	90685
		5 mL multi-dose vial	12.5 (0.25 mL)	§§		158	90687
		0.5 mL single-dose prefilled syringe	0.0	§§	≥ 3 yrs	150	90686
		0.5 mL single-dose vial	0.0	§§		150	90686
		5 mL multi-dose vial	25.0	§§		158	90688
	Fluzone Intradermal ^{1,7} (IIV4)	0.1 mL single-dose prefilled microinjection system ⁸	0.0	§§	18-64 yrs	166	90630
	Fluzone High-Dose ^{1,6} (IIV3)	0.5 mL single-dose prefilled syringe	0.0	§§	≥ 65 yrs	135	90662
Protein Sciences	FluBlok ¹ (RIV3)	0.5 mL single-dose vial	0.0	0.0	≥ 18 yrs	155	90673
MedImmune	FluMist ^{1,9} (LAIV4)	0.2 mL single-dose prefilled intranasal sprayer	0.0	≤ 0.24 (0.2 ml)	2-49 yrs	149	90672

1. Immunization providers should check Food and Drug Administration approved prescribing information for 2016-17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S. licensed vaccines are available at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm.

2. In 2010, ACIP recommended not to use Afluria^{*} in children younger than age 9 years (age indication per package insert is ≥ 5 years). If no other age-appropriate IIV is available, consider administering Afluria^{*}, for a child aged 5 through 8 years at high risk for influenza complications, after discussing risks and benefits with the parent or guardian. Do not use Afluria^{*} in children younger than age 5 years. This recommendation continues for the 2016-2017 influenza season.

3. The Food and Drug Administration has approved Afluria^{*} for intramuscular administration with the PharmaJet Stratis Needle-Free Injection System for persons age 18 through 64 years.

4. Once entered, discard multi-dose vial and any residual contents, after 28 days.

5. Fluad^{*} includes the adjuvant MF-59.

6. Trivalent inactivated vaccine high-dose: a 0.5-mL dose contains 60 µg of each vaccine antigen (180 µg total).
 7. Quadrivalent inactivated influenza vaccine, Intradermal: a 0.1-mL dose contains 9 µg of each vaccine antigen (36 µg total).

8. Administer Fluzone Intradermal Quadrivalent using the delivery system included with the vaccine. The preferred injection site is over the deltoid muscle.

9. MMWR; August 26, 2016;65(5);1-54, ACIP recommends that FluMist^{*} not be used for the 2016-2017 influenza season.

10. The FluLaval¹ (IIV4) 0.5mL dose is the same for adults and pediatrics.

†† Information not included in package insert. The vaccine viruses are produced in cell culture. While the vaccine is not manufactured in eggs, the seed viruses did pass through eggs so cIIV4 is not considered "egg-free." Estimated to contain <50 femtograms (5x10-8 µg) of total egg protein (of which ovalbumin is a fraction) per 0.5 mL dose of Flucelvax^{*}.

§§ Available upon request from Sanofi Pasteur (1-800-822-2463 or MIS.emails@sanofipasteur.com).